• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Ra Capital Management, L.P. bought $8,183,526 worth of shares (2,700,000 units at $3.03)

    9/25/23 4:30:22 PM ET
    $SBTX
    Specialty Chemicals
    Consumer Discretionary
    Get the next $SBTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    RA CAPITAL MANAGEMENT, L.P.

    (Last) (First) (Middle)
    200 BERKELEY STREET, 18TH FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ARS Pharmaceuticals, Inc. [ SPRY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/21/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/21/2023 P 2,508,691 A $2.97(1) 8,365,465(2) I See Footnotes(2)(6)
    Common Stock 09/21/2023 P 191,309 A $3.83(3) 8,556,774(4) I See Footnotes(4)(6)
    Common Stock 902,904(5) I See Footnotes(5)(6)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    RA CAPITAL MANAGEMENT, L.P.

    (Last) (First) (Middle)
    200 BERKELEY STREET, 18TH FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    RA Capital Healthcare Fund LP

    (Last) (First) (Middle)
    200 BERKELEY STREET, 18TH FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    RA Capital Nexus Fund II, L.P.

    (Last) (First) (Middle)
    200 BERKELEY STREET, 18TH FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Kolchinsky Peter

    (Last) (First) (Middle)
    C/O RA CAPITAL MANAGEMENT, L.P.
    200 BERKELEY STREET, 18TH FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Shah Rajeev M.

    (Last) (First) (Middle)
    C/O RA CAPITAL MANAGEMENT, L.P.
    200 BERKELEY STREET, 18TH FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    Explanation of Responses:
    1. This transaction was executed in multiple trades at prices ranging from $2.75 to $3.74; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes, upon request, to provide full information to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected.
    2. Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
    3. This transaction was executed in multiple trades at prices ranging from $3.75 to $3.90; the price reported above reflects the weighted average purchase price. The reporting person hereby undertakes, upon request, to provide full information to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer regarding the number of shares and prices at which these transactions, and all other transactions reported in this Form 4, were effected.
    4. Held directly by the Fund.
    5. Held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
    6. RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
    Remarks:
    Dr. Peter Kolchinsky, a Managing Partner of the Adviser, serves on the Issuer's board of directors.
    /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P. 09/25/2023
    /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC the General Partner of RA Capital Healthcare Fund, L.P. 09/25/2023
    /s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund II GP, LLC the General Partner of RA Capital Nexus Fund II, L.P. 09/25/2023
    /s/ Peter Kolchinsky, individually 09/25/2023
    /s/ Rajeev Shah, individually 09/25/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBTX

    DatePrice TargetRatingAnalyst
    4/4/2022$25.00 → $3.50Buy → Neutral
    Goldman
    4/1/2022$25.00 → $1.80Outperform → Mkt Perform
    SVB Leerink
    4/1/2022$32.00 → $6.00Buy → Hold
    Stifel
    4/1/2022Buy → Neutral
    H.C. Wainwright
    11/12/2021$42.00 → $25.00Outperform
    SVB Leerink
    8/16/2021$46.00 → $49.00Outperform
    SVB Leerink
    More analyst ratings